KATHRYN SHIRLEY: Open Payments
NPI 1639500465 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$686 in 23 payments from 14 companies in 2025. Trend: 2023 $2,699 · 2024 $2,098 · 2025 $686
Food & beverage: $606Education: $80
| Company | Payments | Amount |
|---|---|---|
| Stemline Therapeutics Inc. | 2 | $148 |
| Merck Sharp & Dohme LLC | 4 | $97 |
| Janssen Biotech, Inc. | 2 | $95 |
| GENZYME CORPORATION | 2 | $62 |
| AstraZeneca Pharmaceuticals LP | 2 | $61 |
| ABBVIE INC. | 2 | $52 |
| Celgene Corporation | 2 | $40 |
| Incyte Corporation | 1 | $25 |
| PFIZER INC. | 1 | $21 |
| Blueprint Medicines Corporation | 1 | $19 |
Products named: Orserdu, KEYTRUDA, DARZALEX, OPDIVO, LYNPARZA, QFITLIA, EPKINLY, SARCLISA.
Industry payments across TX — which companies pay providers there.
